BRIEF-Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data

Enliven

Enliven

ELVN

0.00

June 11 (Reuters) - Enliven Therapeutics Inc ELVN.O:

  • ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE PHASE 1 CLINICAL DATA AND ALIGNMENT WITH FDA ON KEY PHASE 3 TRIAL DESIGN COMPONENTS

  • ENLIVEN THERAPEUTICS - REPORTS 61% OVERALL MMR AND 48% MMR AT 24 WEEKS IN 80 MG QD PHASE 1B COHORT

  • ENLIVEN THERAPEUTICS - REPORTS 67% OVERALL MMR AND 55% MMR AT 24 WEEKS IN PHASE 1B PATIENTS WITH 1 OR 2 PRIOR TKIS

  • ENLIVEN THERAPEUTICS - REPORTS FAVORABLE SAFETY PROFILE WITH 161 PATIENTS AND 35 WEEK MEDIAN TREATMENT DURATION

  • ENLIVEN THERAPEUTICS - REACHES FDA ALIGNMENT ON 80 MG QD PHASE 3 DOSE AND 2L+ PATIENT POPULATION FOR ENABLE-2 TRIAL

  • ENLIVEN THERAPEUTICS - ENABLE-2 PIVOTAL TRIAL EXPECTED TO INITIATE IN SECOND HALF OF 2026

Source text: ID:nPn5JLQGga

Further company coverage: ELVN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.